SAMSUNG PHARMACEUTICAL.CO.,Ltd.: debt-to-equity, ROE and more
KOSPI, Legal name SAMSUNG PHARMACEUTICAL.CO.,Ltd.
Latest figures are the FY2025 separate summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 38.3%
- Equity ratio
- 72.3%
- ROE
- 9.5%
- Op. margin
- -39.2%
- Rev. growth
- 4.0%
- Interest coverage
- n/a
Condition flags
- Latest operating profit is not above zero, or not reported.
- Operating loss for 5 straight years.
- Total equity is above paid-in capital. Not capital-impaired.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
No dividend data yet for this company.
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 separate | 14.3% | 87.5% | -31.6% | -33.0% | n/a |
| FY2022 separate | 14.9% | 87.0% | -24.5% | -26.9% | -5.6% |
| FY2023 separate | 20.5% | 83.0% | -32.0% | -34.7% | 0.2% |
| FY2024 separate | 21.3% | 82.4% | -13.3% | -33.5% | -14.7% |
| FY2025 separate | 38.3% | 72.3% | 9.5% | -39.2% | 4.0% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩54.9B | ₩51.8B | ₩52.0B | ₩44.3B | ₩46.1B |
| Operating profit | -₩18.1B | -₩14.0B | -₩18.0B | -₩14.8B | -₩18.1B |
| Pre-tax income | -₩40.3B | -₩25.1B | -₩23.7B | -₩14.1B | ₩11.5B |
| Net income | -₩40.3B | -₩25.1B | -₩24.8B | -₩14.1B | ₩11.5B |
| Total assets | ₩145.5B | ₩117.9B | ₩93.5B | ₩128.5B | ₩167.4B |
| Total liabilities | ₩18.2B | ₩15.3B | ₩15.9B | ₩22.6B | ₩46.4B |
| Total equity | ₩127.3B | ₩102.6B | ₩77.6B | ₩105.9B | ₩121.0B |
| Paid-in capital | ₩33.6B | ₩33.6B | ₩33.6B | ₩47.1B | ₩47.1B |
| Debt/equity (source value) | 14.3% | 14.9% | 20.5% | 21.3% | 38.3% |
Company outline (FSC)
- Market
- KOSPI
- Fiscal year end
- Dec
- Founded
- 1929-08-15
- Listed
- 75/07/04
- Employees
- 87
- Auditor
- 삼덕회계법인
- Audit opinion
- 적정의견
- Corporate reg. no.
- 1101110032568
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for 삼성제약Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.